Jianda Yuan
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Immunotherapy and Immune Responses, CAR-T cell therapy research, T-cell and B-cell Immunology, Immune cells in cancer
Most-Cited Works
- → Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer(2015)7,864 cited
- → Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma(2014)4,353 cited
- → Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET(2012)3,679 cited
- → Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma(2012)2,048 cited
- → Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab(2016)540 cited
- → Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido(2011)518 cited
- → Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial(2010)457 cited
- → Single‐institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting(2010)420 cited
- → CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit(2008)341 cited
- → Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy(2016)329 cited